Navigation Links
Hospital to Hold MRSA Briefing for Media and Community Leaders
Date:10/30/2007

Dr. James Rahal, Infectious Disease Specialist, also available as Expert Resource

FLUSHING, N.Y., Oct. 30 /PRNewswire-USNewswire/ -- The following is being issued by New York Hospital Queens:

WHAT: A special briefing on methicillin-resistant Staphylococcus

aureus(MRSA) is scheduled for media and community leaders.

James Rahal, M.D., and a team of infectious disease

specialists from New York Hospital Queens will address the

basis of concern about this infection. They will discuss the

risks, and address the fear caused by recent cases of

community-acquired MRSA infection in the New York area.

During the briefing, the date and location of a community

education program is expected to be announced.

WHEN: Thursday, November 1, 2007 at 10 a.m.

WHERE: New York Hospital Queens 56-45 Main Street, Flushing NY

11355

Lang Auditorium (please leave 15 minutes for access from

parking area)

FYI: Methicillin-resistant Staphylococcus aureus (MRSA) is a type

of Staph that is resistant to commonly used antibiotics. MRSA

infections occur most frequently among persons in hospitals

and healthcare facilities (such as nursing homes and dialysis

centers) who have weakened immune systems.

MRSA infections that are acquired by healthy persons in the

community who have not been recently (within the past year)

hospitalized or had a medical procedure are known as

Community Acquired-MRSA infections (CA-MRSA). These CA-MRSA

infections are usually manifested as skin infections, such as

pimples, boils, or abscesses; and rarely, pneumonia. For

ba
'/>"/>

SOURCE New York Hospital Queens
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
2. Common Preterm Labor Drug Has More Side Effects Than Alternative, Finds Study from Packard Childrens Hospital and Stanford
3. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
4. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
5. Nektar Threraputics Announces Phase 2a Clinical Results Regarding the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative Hospital-Acquired Pneumonia Presented at the Annual American Thoracic Society International Conference
6. Six Important Things to Know About Preventing Hospital Infections
7. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
8. Hospitalization Rates for Coronary Artery Disease Decline in the U.S.
9. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
10. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
11. OREXIGEN Therapeutics Announces Sustained-Release Formulation of Zonisamide Shows Improved Tolerability When Compared to Immediate Release Formulation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
(Date:1/15/2014)... Fla. , Jan. 15, 2014  In an unprecedented effort to ... TB in ambulances and other transport vehicles, an advanced and portable ... rescue personnel for the first time. In order ... with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... Nov. 1, 2011 Lexicon Pharmaceuticals, Inc. ... on discovering and developing breakthrough treatments for human disease, ... results for the three and nine months ended September ... studies of LX4211 and LX1032 have provided further validation ...
... BEIJING, Nov. 1, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, ... leading China-based advanced in-vitro diagnostic ("IVD") company, today announced ... the second fiscal quarter ended September 30, 2011 ("2Q ... 2011. The Company,s senior management will host ...
Cached Medicine Technology:Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results 2Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results 3Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results 4Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results 5Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results 6Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results 7Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results 8China Medical Technologies to Announce Results for the Second Fiscal Quarter Ended September 30, 2011 on November 18, 2011 2
(Date:4/18/2014)... worst memories? How did it make you feel? According ... personal experience, such as how sad you were or ... especially when you can,t stop thinking about it. ... the context of the memories, rather than how you ... alleviate the negative effects of these memories, a new ...
(Date:4/18/2014)... lead to potential new treatments for breaking the cycle ... Fibrosis, or scarring, is a hallmark of the disease, ... lead to serious organ damage and, in some cases, ... on findings made by Swati Bhattacharyya, PhD, research assistant ... specific protein plays in promoting fibrosis. , "Our ...
(Date:4/17/2014)... Ill. One of the most popular vaccine brands ... And doctors may be overlooking some cost factors when ... a more expensive option, according to a new study ... vaccines to administer can be driven by numerous factors," ... and a professor of computer science and of mathematics ...
(Date:4/17/2014)... review published in the April issue of Immunity ... Institute for Medical Research, says it,s time to take ... to treating sepsis, which kills millions worldwide every ... when molecules released into the bloodstream to fight an ... is necessary for maintaining good health without inflammation, ...
(Date:4/17/2014)... as 10 million older Americans suffer from depression, often ... However, new research a project that followed the ... years found that Internet use among the elderly ... 30 percent. , "That,s a very strong effect," said ... information studies and media who led the project. "And ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2
... Madison, WI December 6 2010 -- An expansion ... if ever, been grown can be problematic for some ... of calcium and/or magnesium carbonate are notoriously iron deficient. ... are estimated to reduce soy bean production by 12.5 ...
... is a powerful therapy to prevent recurrence among certain follicular ... led by the University of Pennsylvania School of Medicine. The ... are marked by a specific protein that may be present ... cancer -- receive a vaccine made from their own tumor ...
... A new drug appears to help chronic myeloid leukemia ... second-line drugs have failed them or because their cancer cells ... researchers reported at the 52nd Annual Meeting of the American ... the drug ponatinib produced major or complete hematologic responses (absence ...
... The next generation of drug therapies and ... are evolving as researchers continue to better understand ... today at the 52nd Annual Meeting of the ... for the standard treatment of advanced asymptomatic follicular ...
... ORLANDO, Fla. Two janus kinase (JAK) inhibitors ... ) in patients, say Mayo Clinic ( http://www.mayoclinic.org/ ... clinical trials at the 52nd annual meeting of ... ) (ASH) Dec. 4𔃅 in Orlando. VIDEO ...
... medication to remove the resulting excess iron remains the ... in young patients with sickle cell anemia, according to ... St. Jude Children,s Research Hospital. The study compared ... problem of iron overload caused by chronic transfusion therapy. ...
Cached Medicine News:Health News:Iron deficiency in soil threatens soybean production 2Health News:Personalized vaccine for lymphoma patients extends disease-free survival by nearly 2 years 2Health News:Personalized vaccine for lymphoma patients extends disease-free survival by nearly 2 years 3Health News:Phase I trial indicates ponatinib may thwart most resistant CML 2Health News:New standards of care and novel treatment options for several forms of lymphoma unveiled 2Health News:New standards of care and novel treatment options for several forms of lymphoma unveiled 3Health News:New standards of care and novel treatment options for several forms of lymphoma unveiled 4Health News:New standards of care and novel treatment options for several forms of lymphoma unveiled 5Health News:New standards of care and novel treatment options for several forms of lymphoma unveiled 6Health News:New standards of care and novel treatment options for several forms of lymphoma unveiled 7Health News:New standards of care and novel treatment options for several forms of lymphoma unveiled 8Health News:New standards of care and novel treatment options for several forms of lymphoma unveiled 9Health News:JAK inhibitors producing significant response in myelofibrosis patients 2Health News:JAK inhibitors producing significant response in myelofibrosis patients 3Health News:2 studies provide insight into stroke risk and prevention in young sickle cell anemia patients 2Health News:2 studies provide insight into stroke risk and prevention in young sickle cell anemia patients 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: